Pharmalot... Pharmalittle... Good Morning

A MESSAGE TO OUR READERS: As the editor of this site for the past five years, I want to make a sincere apology to every Pharmalot reader for the recent tech problems. We have overcome most of the difficulties, but some bugs remain. The latest glitch is an inability to post images this morning. Nonetheless, I have been assured that IT is working through the to-do list. Meanwhile, I want to thank you for your patience and loyalty. And now... a few tidbits...

Human Genome Rejects $2.6B Bid From Glaxo, Seeks Higher Offers (Reuters)

Amgen To Assume Some Enbrel Sales Work From Pfizer (Dow Jones)

Roche Will Not Extend Bid For Illumina (Pharma Times)

Congressional Panels Plan Votes On User Fee Bills Next Week (Dow Jones)

Parents Say Bad Tylenol Killed Their Baby (Courthouse News Service)

Merck Has Won Five Of Six Fosamax Lawsuits (Associated Press)

Acne Med Tied To Doubled Risk Of Eye Problems (Reuters)

South Africa Will Only Buy Certain Drugs Produced Locally (InPharma Technologist)

J&J Gains EU Clearance For $21B Synthes Deal (Reuters)

Seniors Halt Heart Drugs In Medicare Donut Hole (Health Day)

Abbott Reports Two Relapses In Hep C Trial (Bloomberg News)

Boehringer Hep C Drugs Cured 82 Percent In Trial (Bloomberg News)

Medivir Hep C Drug Cured 80 Percent Following Treatment (Bloomberg News)

EDITOR'S NOTE: Please check this post for updates throughout the morning